


BRINGING INNOVATIONS TO LIFE

STEP BY STEP

ROUND 2
INFORMATION SESSION

Biointellect Venturer

Thursday, 24 September 2026



Biointellect Venturer Round 2 Information Session

Presenters:



Leah Goodman

Chief Executive Officer
Biointellect



Jeremy Yang

Program Manager, Pre-Award
Biointellect Venturer



Greiciely André

Program Manager, Post-Award
Biointellect Venturer

Acknowledgment of Country

*We acknowledge the Traditional
Owners of the land on which we meet
today and pay our respects to Elders
past and present*



Purpose of Today's Session

This session will provide applicants with a clear understanding of the Biointellect Venturer incubator and Round 2, including:

- Who Biointellect is
- The purpose and scope of the Biointellect Venturer incubator program
- Round 2 of Biointellect Venturer
 - Eligibility requirements
 - Application and selection process
 - Selection criteria
 - Key dates
- Q/A to conclude the session

Housekeeping

Questions?

- Please submit any questions through the Q&A function
- You may choose to submit questions anonymously if you prefer
- Feel free to upvote questions from other attendees
- Questions will be addressed during the Q&A at the end of the session
- Questions relating to a specific applicant or technology should be directed to venturer@biointellect.com
- Please do not include confidential or commercially sensitive information in your question

This Information Session is being recorded

- The approved recording and slides presented will be published on the Biointellect Venturer website following the session
- Attendees will be advised when the materials are available

Introducing Biointellect

Biointellect

**BRINGING
INNOVATIONS
TO LIFE**

STEP BY STEP

2012

Biointellect's Strategic Advisory Services

- Our consulting heritage with deep networks across industry, academia, and government.
- Provides SMEs with the specialised guidance needed to de-risk development, navigate regulation, and attract follow-on investment.

2024

Full-Service CRO


- Boutique CRO services built for velocity and quality.
- Bespoke, science-driven model that adapts to the specific needs of each study.
- Integrated in-house regulatory advice enables data commercialisation success.

2025

Biointellect Venturer

- Australia's first national virtual incubator – launched on 17 Nov 2025.
- MRFF funding to focus on innovations for the prevention of infectious disease.

Program Overview



Jeremy Yang

Program Manager, Pre-Award
Biointellect Venturer

Biointellect Venturer: Australia's national incubator for infectious disease innovation




Accelerating Australian vaccine and infectious disease innovation for global impact

- Established with **AUD 32.9 million** through the Australian Government's **MRFF 2024 BioMedTech Incubator (BMTI)** Grant Opportunity.
- Delivery of two national cohort intakes and a dedicated top-up funding round for high-potential projects.
- Focusing on SMEs developing innovations for the prevention of infectious diseases.
- Providing catalytic non-dilutive **funding, strategic guidance** and **resources** to accelerate breakthroughs to attract **follow-on funding and investment**.

Long-Term Ambition

- **Boost local innovation and commercialisation** to benefit all Australians and global public health.
- **Attract diversified funding** to create a sustainable incubator program.

The Biointellect Venturer Team



Biointellect Venturer's Inaugural Funding Round

\$10.48M

Awarded in Round 1

6

Australian infectious disease
innovations funded

**ENA Respiratory Pty
Ltd**

\$2.98M

SAMMVax Pty Ltd

\$2.0M

**Saccharide
Therapeutics Pty Ltd**

\$1.5M

**Ebivanta Therapeutics
Pty Ltd**

\$1.5M

**Proboxis
Biotechnology Pty Ltd**

\$1.5M

AdaptiVax Pty Ltd

\$1.0M

Biointellect Venturer Round 2: Funding structure and approach



- Total of **AUD 8.5 million** non-dilutive funding is available for Round 2.
- Round 2 is Biointellect Venturer's final cohort intake through the current MRFF-funded BioMedTech Incubator Grant Opportunity.



- **TRL 3-4:** eligible for up to AUD 1.5 million
- **TRL 5-6:** eligible for up to AUD 3 million

Technologies at TRL 2 may be considered in exceptional cases, if about to progress to TRL 3 or have a credible plan to achieve TRL 4 within the Biointellect Venturer funded project period.



- Selected SMEs may be eligible to apply for additional top-up funding.
- The total funding awarded to an individual project across the program will not exceed **AUD 5 million**.




- Successful SMEs will have up to **20 months** to complete project activities.
- Funding is released in milestone-based tranches aligned to commercially relevant milestones and Go/No-Go points.

Biointellect Venturer provides SMEs with more than just funding




Goal is to build both the technology **and** capabilities to enable long-term success

Eligible use of funds: Example activities



Eligibility Criteria



Eligibility Criteria - Technology

Category	Eligible	Ineligible
Areas of focus	• The technology's lead indication must directly address the prevention of a defined infectious disease in humans. • Technologies targeting zoonotic and vector-borne diseases, or cancers caused by infectious agents, are eligible only where the proposed technology is intended for direct use in humans.	• Technologies targeting non-infectious diseases • Technologies focusing on the treatment or management of infectious disease without a preventative component (e.g. preventing progression of established disease). • Technologies for the management or treatment of another condition that directly or indirectly affects infection risk.

Eligibility Criteria - Technology

Category	Eligible	Ineligible
Modalities	• Prophylactic vaccines • Prophylactic therapeutics, direct and indirect • Direct: directly targets, binds to or neutralises the pathogen itself • Indirect: targets human host cells or the immune system to prevent establishment of infection • Vaccine platform and enabling technologies • Supporting the development of multiple preventative vaccines or therapeutics products targeting different pathogens • That could meaningfully enable or enhance vaccine or prophylactic therapeutic efficacy, and can be applied across a range of pathogens with a direct product-translation pathway	• Diagnostics • Devices (e.g. delivery systems) • Therapeutic interventions intended primarily to treat existing infections, progression of infection or diseases • Host-directed therapies that reduce symptoms after infection onset • Artificial Intelligence (AI) and digital health tools • Software as a medical device (SaMD) • Interventions which act as an anti-infective e.g. topical antiseptics or surface disinfectant

Eligibility Criteria - Technology

Category	Eligible	Ineligible
Stage of Development	- Technologies at TRL 3 – 6 - Technologies at TRL 2 may be considered in exceptional cases if about to progress to TRL 3 or have a credible plan to achieve TRL 4 within the Biointellect Venturer funded project period <i>For platform and enabling technologies, a difference in TRL between the lead indication or product utilising the platform or enabling technology and the broader underlying platform or enabling technology does not in itself deem the technology ineligible.</i>	Technologies at TRL < 3 or > 6 (TRL 2 in scope by exception)


Eligibility Criteria – Applicants and Intellectual Property

Category	Eligible	Ineligible
Applicants / entity	- Australian SME (registered incorporated Australian entity with an ABN / ACN and < 199 employees) - Research teams (Universities and MRIs) that commit to incorporating a new company that meets the SME requirements prior to award of funding	- Large companies (>200 employees), unincorporated entities, sole traders, companies registered outside of Australia <i>Biointellect Venturer funding will not cover the cost of company formation or incorporation</i>
Intellectual Property	- Transferable rights to any required background IP is held or secured, with access on commercial terms for market entry - Applicants pre-incorporation: - Demonstrate a credible plan to secure and transfer required IP to the new entity before execution of the funding agreement - Provide a written undertaking from each relevant licensor confirming the applicant's right to secure transferable rights to the required background intellectual property on commercial terms (subject to the funding being awarded and the venture being incorporated).	No Australian IP ownership or access rights

Other Eligibility Criteria Overview

Category	Criterion
Letter of support	Applicants must provide a formal letter of support: • from the Board/Executive (for established companies) • from the Business Development/Tech Transfer office (for researcher-led teams at universities or MRIs).
Reporting requirements	Applicants must agree to program reporting and monitoring, including submission of outcomes data and other required metrics throughout the program.

Application and Selection Process



Application Assessment, Review and Selection Process

Applications are assessed through a structured, multi-stage process:

1. EOI



- Applicants submit an EOI
- EOIs are screened for eligibility by Biointellect Venturer Team

2. Independent Review / Targeted Due Diligence



- Eligible EOIs undergo targeted due diligence
- EOIs reviewed by independent reviewers and shortlist confirmed by Investment Review Committee (IRC) assessment

3. Full Application / Interview



- Shortlisted EOIs are invited to submit a full application
- IRC assessment with input from the Consumer Advisory Group (CAG)
- Panel interview for shortlisted applicants

4. Final Selection and Award



- Final recommendations for funding are endorsed by the Biointellect Venturer Steering Committee and approved by the Biointellect Board before award and contracting

Phase 1 – Expression Of Interest (EOI)

1 | Applicants submit a non-confidential EOI outlining:

- Alignment with eligibility criteria
- Technology overview and stage of development
- Unmet need and impact
- Competitive landscape and differentiation
- IP position
- Partnerships, funding and investment
- Proposed Biointellect Venturer project and funding request
- Progression beyond the Biointellect Venturer project
- Team capability and resource

2 | EOIs screened for eligibility by the Biointellect Venturer team

Phase 2 – Independent Review / Targeted Due Diligence

1 | Eligible EOIs undergo targeted due diligence by the Biointellect Venturer team and expert advisers

2 | EOIs and associated due diligence findings are assessed by the independent reviewers and shortlist confirmed by the IRC

3 | Shortlisted EOIs are submitted for endorsement by the Biointellect Venturer Steering Committee and approval by the Biointellect Board, before progressing to Phase 3 (Full Application)

Phase 3 – Full Application / Interview

1 | Approved shortlisted applicants are invited to prepare and submit a full application that expands on the EOI and may include:

- Detailed unmet need, target market and opportunity
- Comprehensive technology description and TPP
- Full competitor analysis
- IP strategy
- Further background on team capability
- Detailed project plan for the proposed funding period, including budget, milestones, Go/No-Go points
- Detailed commercialisation strategy including partners, follow-on funding
- Risk assessment and mitigation plan

2 | The IRC, with input from the CAG and technical experts where required, assess full applications against key selection criteria

3 | Shortlisted applicants are invited to participate in a panel interview


Phase 4 – Final Selection and Award

1 | Outputs from the applicant interviews inform the final funding recommendations

2 | Funding recommendations are submitted to the Biointellect Venturer Steering Committee for endorsement and subsequently reviewed and approved by the Biointellect Board

3 | Successful awardees proceed to contracting prior to onboarding and project commencement

Key Dates – EOIs now open!



Selection Criteria



Greiciely André

Program Manager, Post-Award

Biointellect Venturer



Selection Criteria

Biointellect Venturer assesses applications based on:



**Unmet Need and
Impact (20%)**



**Scientific and
Technical Merit (25%)**



Project Plan (15%)



**Team Capability and
Resources (15%)**



**Translation and
Commercialisation (25%)**

Selection Criteria

Unmet Need and Impact (20%)

- A proposed solution that is novel and differentiated
- A solution that addresses a clearly defined public health or clinical unmet (or underserved) need.
- Clear articulation of the solution's value proposition
- Clear articulation of how the solution could deliver meaningful population-level and/or market impact.
- Clear competitive advantage or differentiation from current standard of care, solutions available or solutions in development.

Scientific and Technical Merit (25%)

- A robust scientific rationale.
- Clear articulation and validation of the mechanism of action of the intervention.
- Data confirming the intervention is effective in pre-clinical models.
- Supportive data that demonstrate feasibility, reproducibility, and potential for production at scale.

Selection Criteria

Project Plan (15%)

- Well-defined and milestone-driven.
- Aligns with the critical path towards the next key value inflection point and the broader path to market.
- Proposed activities are supported and justified by measurable deliverables, clear Go/No-Go decision points, identification of key risks and associated mitigation strategies and realistic timelines
- An appropriate, justified budget aligned with project scope and stage of development.

Team Capability and Resources (15%)

- A committed, multidisciplinary and diverse team.
- The required track-record, expertise, resources, and access to required infrastructure or partners to achieve the proposed milestones and objectives of the proposed project and ultimately, position the technology as an attractive opportunity for follow-on investment.

Selection Criteria

Translation and Commercialisation (25%)

- A credible translation, development and commercialisation plan and path to market covering:
 - Follow-on funding/investment strategy
 - Plans for partnerships/collaborations
 - Realistic strategy to advance to the next stage of development, TRL and/or value inflection point.
- An appropriate regulatory pathway
- Favourable IP position
- Justified target market
- Together, there is evidence of a clear commercial and/or commercialisation opportunity.
- While some infectious disease interventions may hold uncertain commercial return, a clear mechanism and pathway to commercialisation must be evident.

Preparing your EOI application



Jeremy Yang

Program Manager, Pre-Award
Biointellect Venturer

Grant Writing Workshop – Strengthen your EOI!



ROUND 2

Considering applying for Round 2?

Gain practical insights into building a stronger EOI.

GRANT WRITING WORKSHOP



Wednesday,
30th September 2026
11:00 am - 12:00 pm AEST



Online,
Microsoft Teams

Biointellect Venturer is delivered by Biointellect with support from the Australian Government through the Medical Research Future Fund (MRFF) 2024 BioMedTech Incubator Grant Opportunity.



The workshop will cover:

- **Key insights and learnings from Round 1** of Biointellect Venturer
- What reviewers look for in a **competitive EOI**
- How to **build a compelling application narrative** from unmet need to market impact
- How to **communicate a realistic, milestone-driven path** to commercialisation
- **Common application pitfalls and practical tips** for preparing clear, concise and evidence-based responses



Scan the QR code to register

How To Apply



Additional program information, Round 2 Funding Guidelines, FAQs and the Round 2 Information Session recording are available at:
biointellect.com/biointellect-venturer



Connect with the Biointellect Venturer team at:
venturer@biointellect.com



Submit your EOI at:
venturer.grantplatform.com



**EOIs close 16 October 2026 at
4:00pm AEDT!**

Q&A

- Please submit questions through the Q&A function
- You can choose to submit your question anonymously if you prefer
- Upvote questions you would also like answered
- Questions relating to a specific applicant or technology should be directed to venturer@biointellect.com
- Please do not include confidential or commercially sensitive information in your question

Thank you for attending our Round 2 Information Session!



**Accelerating Australian vaccine and infectious disease innovation
for global impact**

Funded by the Australian Government's Medical Research Future Fund (MRFF) through the 2024 BioMedTech Incubator grant opportunity.

© Biointelect 2026. All rights reserved.

Get in touch



Email:
venturer@biointelect.com



LinkedIn:
[linkedin.com/company/biointelect](https://www.linkedin.com/company/biointelect)



Website:
<https://www.biointelect.com/biointelect-venturer/>

Sign up for our mailing list →

